Skip to content
AnalystLens

Royalty Pharma 8-K Report, Financial Results (May 9, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed May 9, 2024
Period End
May 9, 2024
Security
RPRX
In the record · 2020–202610-K610-Q208-K80

RPRX filed 6 annual reports (10-K), 20 quarterly reports (10-Q) and 80 current reports (8-K) between 2020 and 2026.

  1. Material agreement8-K · Jul ’21Jul ’21
  2. Impairment8-K · Dec ’22Dec ’22
  3. Material agreement8-K · May ’26May ’26

01—Abstract

Summary

Summary of the 8-K filed May 9, 2024. Cited figures are marked; the original filing is the authoritative source.

Royalty Pharma plc (Nasdaq: RPRX) reported first quarter 2024 results on May 9, 2024, as described in Exhibit 99.1 (press release) furnished under Item 2.02.

Portfolio Receipts were $717 milliona, down 37% from $1,131 million in the prior-year quarter, reflecting a high comparison base: the first quarter of 2023 included a $475 million Zavzpret milestone payment and a $29 million Airsupra payment. Royalty Receipts grew 14% to $705 million, driven by Trelegy, the cystic fibrosis franchise and incremental Evrysdi royalties acquired in October 2023. Net cash provided by operating activities was $665 million, versus $1,034 million a year earlier, and Adjusted EBITDA (non-GAAP) was $656 million.

Portfolio Cash Flow (non-GAAP) was $584 millionb. Management confirmed full-year 2024 guidance, with Portfolio Receipts expected at $2,600 million to $2,700 million, excluding future transactions. That guidance includes expected Royalty Receipts growth of 5% to 9%.

The company also announced an agreement to acquire royalties and milestones on Sanofi's frexalimab from ImmuNext for approximately $525 millionc in cash including estimated transaction costs. Capital Deployment in the quarter was $93 million, and the company cited more than $3.5 billion of financial capacity including cash and leverage. Cash and cash equivalents were $843 million and total debt principal was $6.3 billion as of March 31, 2024.

The filing also highlights a development-stage portfolio of 15 therapies, 11 of which are in Phase 3 development or under regulatory review. Key expected events over the next year include FDA filings for aficamten and pelabresib, pivotal results for seltorexant and Tremfya in Crohn's disease, and an FDA action date for KarXT. The release states a commitment to grow the dividend by a mid-single-digit percentage annually.

02—Key points

Key Highlights

  1. Portfolio Receipts fell 37% to $717 million from $1,131 million, primarily due to a $475 million Zavzpret milestone in Q1 2023 that did not recur.
  2. Royalty Receipts grew 14% to $705 million, led by Trelegy, the cystic fibrosis franchise and Evrysdi.
  3. Net cash provided by operating activities was $665 million, down from $1,034 million; Adjusted EBITDA was $656 million and Portfolio Cash Flow was $584 million.
  4. Full-year 2024 Portfolio Receipts guidance of $2,600 million to $2,700 million was confirmed, excluding future transactions.
  5. Agreed to acquire royalties and milestones on Sanofi's frexalimab from ImmuNext for approximately $525 million in cash including estimated transaction costs.
  6. Development-stage portfolio grew to 15 therapies, with 11 in Phase 3 development or regulatory review.
  7. Cash and cash equivalents of $843 million and total debt principal of $6.3 billion as of March 31, 2024; financial capacity stated at more than $3.5 billion.

03—Questions

Frequently Asked Questions

  1. Why did Portfolio Receipts decline so sharply year over year?

    The decline reflects a high base of comparison. Milestones and other contractual receipts were $12 million in Q1 2024 versus $515 million in Q1 2023, which included a $475 million Zavzpret milestone payment and a $29 million Airsupra payment. Royalty Receipts actually rose 14%.

  2. What is the company's full-year 2024 outlook?

    Portfolio Receipts are expected to be between $2,600 million and $2,700 million, excluding transactions announced after the release date. The guidance includes expected Royalty Receipts growth of 5% to 9%, and payments for operating and professional costs are expected at 8% to 9% of Portfolio Receipts. Interest paid is expected to be approximately $160 million.

  3. What new transaction did Royalty Pharma announce?

    The company announced a transaction to acquire royalties and milestones on frexalimab, owned by ImmuNext, for approximately $525 million in cash including estimated transaction costs. Frexalimab is a Sanofi therapy in Phase 3 development for multiple sclerosis and in Phase 2 for systemic lupus erythematosus and Type 1 Diabetes.

  4. How much capital did the company deploy in the quarter?

    Capital Deployment was $93 million in Q1 2024, consisting primarily of the $49 million upfront payment for ecopipam and $36 million in research and development funding support for TEV-'749. Capital Deployment was $618 million in Q1 2023.

  5. What dividend commitment did management make?

    The release states a commitment to grow the dividend by a mid-single-digit percentage annually. Dividends to shareholders were $94 million in Q1 2024 compared with $89 million in Q1 2023.

04—Continue

← View all 8-K filings